Skip to main content
Top
Published in: Drugs & Aging 6/2018

01-06-2018 | Original Research Article

Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients

Authors: Laurent Lafarge, Fouzi Khayi, Anis Bel-Kamel, Nicolas Charhon, Laura Sarfati, Benoit Falquet, Michel Ducher, Laurent Bourguignon

Published in: Drugs & Aging | Issue 6/2018

Login to get access

Abstract

Background

Oral vitamin K antagonists (VKAs) are commonly used in older adults. To ensure the efficiency and safety of these drugs, the international normalized ratio (INR) must be monitored. The time in therapeutic range (TTR) is an internationally recommended assessment of the anticoagulation quality.

Objective

Our study aimed to assess the TTR of VKAs in a hospitalized geriatric population and identify factors associated with low TTR.

Methods

This was a multicenter retrospective study of data from 1899 patients with a mean age of 87 years between 2013 and 2015 in the geriatric units of four French hospitals. The data collection consisted of 2450 VKA prescriptions. We excluded prescriptions with a duration of < 7 days, monitoring with fewer than two INR values and patients with prosthetic heart valves. TTR was assessed using the Rosendaal method. Factors associated with a low TTR (< 50%) were assessed using a non-parametric method.

Results

The mean TTR observed in this population was 42.6%. The TTR was < 50% for 62.5% of the patients included in this study. Significant associations were found between TTR < 50% and aspartate transaminase (AST), alkaline phosphatase (ALT), thyroid-stimulating hormone (TSH), prescription duration, fluconazole instauration, hemoglobin, and C-reactive protein (CRP).

Conclusions

Both our results and those in the literature indicate that TTR in geriatric populations is lower than that in the general population. Most patients had an insufficient TTR, exposing them to an increased risk of thromboembolic and hemorrhagic events. These data provide a perspective on poor-quality anticoagulation and illustrates the difficulty of using VKAs in geriatric patients.
Literature
1.
go back to reference Kazemian P, Oudit G, Jugdutt BI. Atrial fibrillation and heart failure in the elderly. Heart Fail Rev. 2012;17(4–5):597–613.CrossRefPubMed Kazemian P, Oudit G, Jugdutt BI. Atrial fibrillation and heart failure in the elderly. Heart Fail Rev. 2012;17(4–5):597–613.CrossRefPubMed
2.
go back to reference Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–52.CrossRefPubMed Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–52.CrossRefPubMed
3.
go back to reference Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57(11):e101–98.CrossRefPubMed Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57(11):e101–98.CrossRefPubMed
4.
go back to reference Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.CrossRefPubMed Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.CrossRefPubMed
5.
go back to reference Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2016;50(5):e1–88.CrossRef Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2016;50(5):e1–88.CrossRef
6.
go back to reference Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.CrossRefPubMed Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.CrossRefPubMed
8.
go back to reference Montastruc JL, Rousseau V, Chebane L, Abadie D, Bondon-Guitton E, Durrieu G, et al. Hemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA). Eur J Clin Pharmacol. 2015;71(10):1283–4.CrossRefPubMed Montastruc JL, Rousseau V, Chebane L, Abadie D, Bondon-Guitton E, Durrieu G, et al. Hemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA). Eur J Clin Pharmacol. 2015;71(10):1283–4.CrossRefPubMed
9.
go back to reference Vitry AI, Roughead EE, Ramsay EN, Preiss AK, Ryan P, Gilbert AL, et al. Major bleeding risk associated with warfarin and co-medications in the elderly population. Pharmacoepidemiol Drug Saf. 2011;20(10):1057–63.CrossRefPubMed Vitry AI, Roughead EE, Ramsay EN, Preiss AK, Ryan P, Gilbert AL, et al. Major bleeding risk associated with warfarin and co-medications in the elderly population. Pharmacoepidemiol Drug Saf. 2011;20(10):1057–63.CrossRefPubMed
10.
go back to reference Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013;2(1):e000067.CrossRefPubMedPubMedCentral Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013;2(1):e000067.CrossRefPubMedPubMedCentral
11.
go back to reference Lee J, Lee B, Kim K, Ahn H, Suh O, Lee M, et al. Factors affecting warfarin therapy following cardiac valve surgery. Ann Pharmacother. 2002;36(12):1845–50.CrossRefPubMed Lee J, Lee B, Kim K, Ahn H, Suh O, Lee M, et al. Factors affecting warfarin therapy following cardiac valve surgery. Ann Pharmacother. 2002;36(12):1845–50.CrossRefPubMed
12.
go back to reference Rouaud A, Hanon O, Boureau A-S, Chapelet G, Chapelet GG, de Decker L. Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional study. PloS One. 2015;10(3):e0119043.CrossRefPubMedPubMedCentral Rouaud A, Hanon O, Boureau A-S, Chapelet G, Chapelet GG, de Decker L. Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional study. PloS One. 2015;10(3):e0119043.CrossRefPubMedPubMedCentral
13.
go back to reference Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, et al. Oral anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S–88S.CrossRefPubMedPubMedCentral Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, et al. Oral anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S–88S.CrossRefPubMedPubMedCentral
14.
go back to reference Okumura K, Komatsu T, Yamashita T, Okuyama Y, Harada M, Konta Y, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation A multicenter study of its status and infuential factors. Circ J Off J Jpn Circ Soc. 2011;75(9):2087–94. Okumura K, Komatsu T, Yamashita T, Okuyama Y, Harada M, Konta Y, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation A multicenter study of its status and infuential factors. Circ J Off J Jpn Circ Soc. 2011;75(9):2087–94.
15.
go back to reference Shao X-H, Yang Y-M, Zhu J, Zhang H, Liu Y, Gao X, et al. Comparison of the clinical features and outcomes in two age-groups of elderly patients with atrial fibrillation. Clin Interv Aging. 2014;9:1335–42.CrossRefPubMedPubMedCentral Shao X-H, Yang Y-M, Zhu J, Zhang H, Liu Y, Gao X, et al. Comparison of the clinical features and outcomes in two age-groups of elderly patients with atrial fibrillation. Clin Interv Aging. 2014;9:1335–42.CrossRefPubMedPubMedCentral
16.
go back to reference January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.CrossRefPubMed January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.CrossRefPubMed
17.
go back to reference Lehto M, Niiranen J, Korhonen P, Mehtälä J, Khanfir H, Hoti F, et al. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. Pharmacoepidemiol Drug Saf. 2017;26(6):657–65.CrossRefPubMed Lehto M, Niiranen J, Korhonen P, Mehtälä J, Khanfir H, Hoti F, et al. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. Pharmacoepidemiol Drug Saf. 2017;26(6):657–65.CrossRefPubMed
18.
go back to reference Insam C, Méan M, Limacher A, Angelillo-Scherrer A, Aschwanden M, Banyai M, et al. Anticoagulation management practices and outcomes in elderly patients with acute venous thromboembolism: a clinical research study. PloS One. 2016;11(2):e0148348.CrossRefPubMedPubMedCentral Insam C, Méan M, Limacher A, Angelillo-Scherrer A, Aschwanden M, Banyai M, et al. Anticoagulation management practices and outcomes in elderly patients with acute venous thromboembolism: a clinical research study. PloS One. 2016;11(2):e0148348.CrossRefPubMedPubMedCentral
19.
go back to reference Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet Lond Engl. 2007;370(9586):493–503.CrossRef Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet Lond Engl. 2007;370(9586):493–503.CrossRef
20.
go back to reference Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.PubMedCrossRef Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.PubMedCrossRef
21.
go back to reference Ducher M, Cerutti C, Gustin MP, Paultre CZ. Statistical relationships between systolic blood pressure and heart rate and their functional significance in conscious rats. Med Biol Eng Comput. 1994;32(6):649–55.CrossRefPubMed Ducher M, Cerutti C, Gustin MP, Paultre CZ. Statistical relationships between systolic blood pressure and heart rate and their functional significance in conscious rats. Med Biol Eng Comput. 1994;32(6):649–55.CrossRefPubMed
22.
go back to reference White HD, Gruber M, Feyzi J, Kaatz S, Tse H-F, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239–45.CrossRefPubMed White HD, Gruber M, Feyzi J, Kaatz S, Tse H-F, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239–45.CrossRefPubMed
23.
go back to reference Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa T-P. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968–77.CrossRefPubMed Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa T-P. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968–77.CrossRefPubMed
24.
go back to reference Cotté F-E, Benhaddi H, Duprat-Lomon I, Doble A, Marchant N, Letierce A, et al. Vitamin K Antagonist Treatment in Patients With Atrial Fibrillation and Time in Therapeutic Range in Four European Countries. Clin Ther. 2014;36(9):1160–8.CrossRefPubMed Cotté F-E, Benhaddi H, Duprat-Lomon I, Doble A, Marchant N, Letierce A, et al. Vitamin K Antagonist Treatment in Patients With Atrial Fibrillation and Time in Therapeutic Range in Four European Countries. Clin Ther. 2014;36(9):1160–8.CrossRefPubMed
25.
go back to reference Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127(22):2166–76.CrossRefPubMed Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127(22):2166–76.CrossRefPubMed
26.
go back to reference Chan P-H, Li W-H, Hai J-J, Chan EW, Wong ICK, Tse H-F, et al. Time in therapeutic range and percentage of international normalized ratio in the therapeutic range as a measure of quality of anticoagulation control in patients with atrial fibrillation. Can J Cardiol. 2016;32(10):1247.e23–8. Chan P-H, Li W-H, Hai J-J, Chan EW, Wong ICK, Tse H-F, et al. Time in therapeutic range and percentage of international normalized ratio in the therapeutic range as a measure of quality of anticoagulation control in patients with atrial fibrillation. Can J Cardiol. 2016;32(10):1247.e23–8.
27.
go back to reference van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129(5):1155–66.CrossRefPubMed van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129(5):1155–66.CrossRefPubMed
28.
go back to reference Ritschel WA. Handbook of basic pharmacokinetic, including clinical applications. Hamilton: Drug Intelligence Publications; 1986. Ritschel WA. Handbook of basic pharmacokinetic, including clinical applications. Hamilton: Drug Intelligence Publications; 1986.
29.
go back to reference Wolfgang RA, Ritschel WA. Gerontokinetics: pharmacokinetics of drugs in the elderly. 1st edn. Telford:Telford Press; 1988. Wolfgang RA, Ritschel WA. Gerontokinetics: pharmacokinetics of drugs in the elderly. 1st edn. Telford:Telford Press; 1988.
30.
go back to reference van Walraven C, Austin PC, Oake N, Wells P, Mamdani M, Forster AJ. The effect of hospitalization on oral anticoagulation control: a population-based study. Thromb Res. 2007;119(6):705–14.CrossRefPubMed van Walraven C, Austin PC, Oake N, Wells P, Mamdani M, Forster AJ. The effect of hospitalization on oral anticoagulation control: a population-based study. Thromb Res. 2007;119(6):705–14.CrossRefPubMed
31.
go back to reference Debeij J, Cannegieter SC, van Zaane B, van Zanten AP, Rosendaal FR, Gerdes VEA, et al. Major Haemorrhage during Vitamin K antagonist treatment: the influence of thyroid hormone levels. Eur Thyroid J. 2014;3(1):32–7.CrossRefPubMedPubMedCentral Debeij J, Cannegieter SC, van Zaane B, van Zanten AP, Rosendaal FR, Gerdes VEA, et al. Major Haemorrhage during Vitamin K antagonist treatment: the influence of thyroid hormone levels. Eur Thyroid J. 2014;3(1):32–7.CrossRefPubMedPubMedCentral
32.
go back to reference Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131(4):417–30.CrossRefPubMed Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131(4):417–30.CrossRefPubMed
33.
go back to reference Shea MK, Cushman M, Booth SL, Burke GL, Chen H, Kritchevsky SB. Associations between vitamin K status and haemostatic and inflammatory biomarkers in community-dwelling adults. The Multi-Ethnic Study of Atherosclerosis. Thromb Haemost. 2014;112(3):438–44.PubMedPubMedCentral Shea MK, Cushman M, Booth SL, Burke GL, Chen H, Kritchevsky SB. Associations between vitamin K status and haemostatic and inflammatory biomarkers in community-dwelling adults. The Multi-Ethnic Study of Atherosclerosis. Thromb Haemost. 2014;112(3):438–44.PubMedPubMedCentral
34.
go back to reference Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy. 2004;24(10):1311–6.CrossRefPubMed Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy. 2004;24(10):1311–6.CrossRefPubMed
35.
go back to reference Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother. 2005;39(4):632–6.CrossRefPubMed Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother. 2005;39(4):632–6.CrossRefPubMed
36.
go back to reference Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003;15(3):213–6.CrossRefPubMed Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003;15(3):213–6.CrossRefPubMed
37.
go back to reference Vanerio G. International normalized ratio variability: a measure of anticoagulation quality or a powerful mortality predictor. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2015;24(10):2223–8.CrossRef Vanerio G. International normalized ratio variability: a measure of anticoagulation quality or a powerful mortality predictor. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2015;24(10):2223–8.CrossRef
38.
go back to reference Jones C, Pollit V, Fitzmaurice D, Cowan C. Guideline Development Group. The management of atrial fibrillation: summary of updated NICE guidance. BMJ. 2014;348:g3655.CrossRefPubMed Jones C, Pollit V, Fitzmaurice D, Cowan C. Guideline Development Group. The management of atrial fibrillation: summary of updated NICE guidance. BMJ. 2014;348:g3655.CrossRefPubMed
Metadata
Title
Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients
Authors
Laurent Lafarge
Fouzi Khayi
Anis Bel-Kamel
Nicolas Charhon
Laura Sarfati
Benoit Falquet
Michel Ducher
Laurent Bourguignon
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 6/2018
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-018-0551-5

Other articles of this Issue 6/2018

Drugs & Aging 6/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.